Authorized purpose: CEPHX3D processes dental and craniomaxillofacial images to support diagnosis and treatment planning, including three-dimensional models, viewing, segmentation, measurements, and dental-solution design input for patients age 12 and older.
Clinical role
Dental image visualization, segmentation, measurement, implant or trajectory planning, and three-dimensional model support.
Images and patients
CBCT · Dental and craniomaxillofacial anatomy
Key limitation
Keep in mind: Planning outputs do not replace clinical examination or professional judgment; image quality, scan protocol, anatomy, manufacturing, and age or indication limits apply.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: CEPHX3D processes dental and craniomaxillofacial images to support diagnosis and treatment planning, including three-dimensional models, viewing, segmentation, measurements, and dental-solution design input for patients age 12 and older.
Which images or clinical context are in scope?Modality: CBCT Anatomy or clinical context: Dental and craniomaxillofacial anatomy Input: Supported dental CT, cone-beam CT, panoramic, cephalometric, or related radiographic data.
Who uses it?Intended users: Qualified dentists, dental radiologists, oral and maxillofacial surgeons, and trained dental imaging staff.
What does the software produce?Output: Three-dimensional models, measurements, planning views, templates, and reports for professional review.
What is its most important limitation?Key limitation: Planning outputs do not replace clinical examination or professional judgment; image quality, scan protocol, anatomy, manufacturing, and age or indication limits apply.
Clinical takeaway. Clinical role: CEPHX3D processes dental and craniomaxillofacial images to support diagnosis and treatment planning, including three-dimensional models, viewing, segmentation, measurements, and dental-solution design input for patients age 12 and older.
Evidence takeaway. Evidence from the reviewed source record: The exact FDA document reports a quantitative non-clinical validation of 30 CBCT datasets against an expert-refined ground truth (mean DSC: skeletal bone 0.9827, dentition 0.9993, inferior alveolar nerve 0.9861), with reference-standard reliability checked by two independent experts (Overall Global Mean DSC of 0.9905), and a retrospective clinical review of 53 CBCT cases by independent board-certified specialists, with 100% (53/53) rated "Clinically Acceptable" (primary endpoint met). Results are as reported in the FDA submission, not independent validation.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
CEPHX3D processes dental and craniomaxillofacial images to support diagnosis and treatment planning, including three-dimensional models, viewing, segmentation, measurements, and dental-solution design input for patients age 12 and older.
Planning outputs do not replace clinical examination or professional judgment; image quality, scan protocol, anatomy, manufacturing, and age or indication limits apply.
The exact FDA document reports a quantitative non-clinical validation of 30 CBCT datasets against an expert-refined ground truth (mean DSC: skeletal bone 0.9827, dentition 0.9993, inferior alveolar nerve 0.9861), with reference-standard reliability checked by two independent experts (Overall Global Mean DSC of 0.9905), and a retrospective clinical review of 53 CBCT cases by independent board-certified specialists, with 100% (53/53) rated "Clinically Acceptable" (primary endpoint met). Results are as reported in the FDA submission, not independent validation.
Exact FDA submission
Checked 2026-11-14
Packet wording: "Non-clinical performance was established through a quantitative analytical validation of 30 CBCT datasets against an expert-refined "Ground Truth" established via the Refined Automated Segmentation (R-AS) methodology." … "Skeletal Bone: Achieved a mean Dice Similarity Coefficient (DSC) of 0.9827". Read from the exact FDA decision document on 2026-11-14.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
The exact FDA document reports a quantitative non-clinical validation of 30 CBCT datasets against an expert-refined ground truth (mean DSC: skeletal bone 0.9827, dentition 0.9993, inferior alveolar nerve 0.9861), with reference-standard reliability checked by two independent experts (Overall Global Mean DSC of 0.9905), and a retrospective clinical review of 53 CBCT cases by independent board-certified specialists, with 100% (53/53) rated "Clinically Acceptable" (primary endpoint met). Results are as reported in the FDA submission, not independent validation.
FDA source
Exact FDA submission
Checked 2026-11-14
Packet wording: "Non-clinical performance was established through a quantitative analytical validation of 30 CBCT datasets against an expert-refined "Ground Truth" established via the Refined Automated Segmentation (R-AS) methodology." … "Skeletal Bone: Achieved a mean Dice Similarity Coefficient (DSC) of 0.9827". Read from the exact FDA decision document on 2026-11-14.
Sensitivity is not a product-wide endpoint for this system or software function. Compare only an exact endpoint, threshold, population, version, and source if one is later verified.
Reported specificity
Not applicable
Not applicable
Not applicable
Checked 2026-09-04
Specificity is not a product-wide endpoint for this system or software function. Compare only an exact endpoint, threshold, population, version, and source if one is later verified.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
K252538 FDA evidence package for CEPHX3D
DesignFDA software substantial-equivalence decision with image-processing, segmentation, measurement, model-rendering, and usability verification
PopulationDental and craniomaxillofacial image studies for patients age 12 and older within the labeled planning workflow
Scopeexact submission
Tested versionCEPHX3D configuration described in K252538
IndependenceSponsor or vendor study
K252538
Manufacturer evidence submitted for the exact FDA decision. It is not independent clinical validation, and local technical, clinical, privacy, security, and workflow acceptance remains necessary.
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
The 2026-09-02 openFDA device-recall snapshot contained no record matched to K252538 by exact native submission identifier. This does not exclude product-family, later, or adverse-event information.
Public source
Exact FDA submission
Checked 2026-09-04
Exact-identifier review does not prove absence of all product-family safety signals.
No separate named-product Medicare payment was identified in the reviewed CMS coverage material. Evaluate the product within the applicable imaging, procedural, or surgical service line and verify payer, site-of-service, and coding assumptions independently.
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: Supported dental CT, cone-beam CT, panoramic, cephalometric, or related radiographic data.
Scope: Exact FDA submission.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: The exact FDA material describes image import, WebGL display, STL model output, and manual segmentation refinement; validate the installed import, export, identity, geometry, and planning workflow locally.
Scope: Exact FDA submission. The exact FDA package describes the indicated input or interface boundary; local interoperability acceptance remains necessary.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Unresolved route: Not established for the exact route.
Scope: Exact FDA submission. The public exact-submission material does not establish the complete deployment topology, hosting responsibility, availability, upgrade path, or service contract.
Confirm processing location, queue ownership, exclusions and exact AI build.
Field checked 2026-09-04 ·
Returned objects
Source context, not route validation: Three-dimensional models, measurements, planning views, templates, and reports for professional review.
Scope: Exact FDA submission.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Unresolved route: Three-dimensional models, measurements, planning views, templates, and reports for professional review.
Scope: Exact FDA submission.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
The exact FDA material describes image import, WebGL display, STL model output, and manual segmentation refinement; validate the installed import, export, identity, geometry, and planning workflow locally.
Exact FDA submission
Checked 2026-09-04
The exact FDA package describes the indicated input or interface boundary; local interoperability acceptance remains necessary.
Only qualified dentists, dental radiologists, oral and maxillofacial surgeons, and trained dental imaging staff should operate or interpret the product. Local onboarding should cover the exact release, supported population, limitations, failure examples, escalation, downtime, and competency documentation.
Monitor by exact hardware, software, model, and algorithm version; patient population; anatomy; protocol; operator; input quality; output edits or overrides; failed studies; repeat acquisition or rework; downstream impact; downtime; incidents; recalls; and updates. Track these product-specific limits: Planning outputs do not replace clinical examination or professional judgment; image quality, scan protocol, anatomy, manufacturing, and age or indication limits apply.
Product family
Checked 2026-09-04
Current vendor material is product-family context for K252538; confirm exact cleared version, enabled options, deployment, and local compatibility.
The exact FDA material describes image import, WebGL display, STL model output, and manual segmentation refinement; validate the installed import, export, identity, geometry, and planning workflow locally.
product family · checked 2026-09-04
Test representative identifiers, orientation, geometry, measurements, units, routing, failure handling, and round trips locally. Current vendor material is product-family context; confirm exact release, enabled options, deployment, and local compatibility.
Use a signed local test set for the supported population and workflow. Include common and difficult cases, exclusions, acquisition variation, failed or low-quality inputs, reviewer overrides, and downstream effects. Planning outputs do not replace clinical examination or professional judgment; image quality, scan protocol, anatomy, manufacturing, and age or indication limits apply.
exact submission · checked 2026-09-04
Define stop-use, escalation, rollback, and revalidation triggers before production use.
Model capital and recurring cost against net staff time after review, throughput, repeat imaging or rework, room time, consumables, infrastructure, training, service, downtime, upgrade, and replacement costs.
product family · checked 2026-09-04
No exact-product price was found in the reviewed public material; productivity or value claims require local evidence.
Monitor by exact hardware, software, model, and algorithm version; patient population; anatomy; protocol; operator; input quality; output edits or overrides; failed studies; repeat acquisition or rework; downstream impact; downtime; incidents; recalls; and updates. Track these product-specific limits: Planning outputs do not replace clinical examination or professional judgment; image quality, scan protocol, anatomy, manufacturing, and age or indication limits apply.
product family · checked 2026-09-04
Revalidate after material software, hardware, model, protocol, interface, or clinical-policy changes. Current vendor material is product-family context; confirm exact release, enabled options, deployment, and local compatibility.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Human reviewedStatus
2026-09-20Last searched
27Fields reviewed
13Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads
The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision material, vendor product page, peer reviewed literature, clinical trial registry, reimbursement policy, fda device recall, literature index, trial registry, fda decision summary, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not publicly available - checked 2026-09-04 - Exact FDA submission
No public list price for the exact cleared configuration was found. Obtain a written quote separating hardware or license basis, implementation, interfaces, infrastructure, training, service, upgrades, renewal, consumables, and exit costs.
Pricing model: Not yet reviewed
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Deployment: Not publicly available - checked 2026-09-04 - Exact FDA submission
The public exact-submission material does not establish the complete deployment topology, hosting responsibility, availability, upgrade path, or service contract.
Data hosting location: Not yet reviewed
Data retention: Not yet reviewed
Documented data use: Not yet reviewed
Hardware requirements: Not yet reviewed
Network requirements: Not yet reviewed
Identity and access: Not yet reviewed
Security: Not verified - checked 2026-09-04 - Exact FDA submission
Public materials reviewed for this exact release do not establish the complete security posture. Request data-flow, identity, audit, encryption, retention, remote-access, vulnerability-management, backup, and incident-response evidence.
Authorized purpose: Second Opinion 3D processes dental CBCT radiographs to identify and mark dentition, maxilla, mandible, inferior alveolar canal and mental foramen, maxillary sinus, nasal space, and airway for review by dental health professionals age 12 and older; it is a concurrent or second reader, not a sole diagnosis.
Authorized purpose: DS Core CBCT Anatomy uses CBCT and digital-impression data to provide tooth and jaw segmentation, inferior-alveolar-nerve-canal segmentation, panoramic-curve support, and registration for dental professionals.
Modality
CBCT
Anatomy
Teeth; jaws; and the inferior alveolar nerve canal
Authorized purpose: Segmentron Viewer is an AI web application for processing and manipulating maxillofacial radiographic images, viewing and segmenting three-dimensional CBCT data, and creating editable STL outputs for educational use.
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.